Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Cyclin-dependent kinase Stories

2014-03-27 08:35:19

Robust antitumor activity of G1's novel CDK4/6 inhibitors to be highlighted in poster on April 7 CHAPEL HILL, N.C., March 27, 2014 /PRNewswire/ -- G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that it will reveal new data on its novel, potent and selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors during a poster...

2013-10-21 13:17:16

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...

2013-04-25 20:25:22

Mount Sinai researchers identify new targets that cause abnormal cell division Blocking certain enzymes in the cell may prevent cancer cell division and growth, according to new findings from researchers at the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai. The discovery is published in the April 25, 2013 issue of the journal Molecular Cell. In order to divide, a cell needs to create copies of its genetic material to provide to the new cells,...

2012-07-16 14:03:26

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development. Dr. Daniel Tenen and colleagues from Harvard University in Boston discovered a new pathway activated by FLT3 mutation. Their...

2011-11-02 10:40:00

DIEPENBEEK, Belgium, November 2, 2011 /PRNewswire/ -- Kinase inhibitor reduces inflammation in the lungs in COPD model with no cardiovascular side effects Amakem NV, a kinase platform company focusing on ophthalmology, today presented further data demonstrating the effectiveness of its 'Localized Drug Action' approach at the Discovery on Target conference in Boston, MA. The Localized Drug Action platform underpins Amakem's lead product, AMA0076...

2011-07-26 13:52:24

Study uncovers several compounds that inhibit cancer cell invasion, but also reveals that cancer drug paclitaxel does the opposite"”it promotes cancer metastasis. Metastasis"”the spread of cancer from the place where it first started to another place in the body"”is the most common reason that cancer treatments fail. To metastasize, some types of cancer cells rely on invadopodia, cellular membrane projections that act like feet, helping them "walk" away from the primary...

2011-06-09 23:33:23

Blocking cyclin D1 might help sensitize tumors to radiation Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors. Many cancers are driven in part by elevated levels of cyclin D1, which allow the cells to escape growth controls and proliferate abnormally. In the new research, reported in the June 9 issue of Nature, researchers discovered that cyclin D1 also...

2010-09-09 07:00:00

SAN DIEGO, Sept. 9 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the initiation of a phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced/refractory hematologic malignancies. Tragara will conduct the study at multiple clinical centers in the United States. In vitro and in vivo data of TG02 have demonstrated biological activity against acute leukemias and multiple myeloma in addition to several solid tumors with unmet medical needs...

2010-07-28 14:34:57

With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of Pittsburgh School of Medicine in Diabetes, a journal of the American Diabetes Association. They also found several cocktails of molecules that drive human beta cells to replicate, as well as important differences between mouse and human beta cells that could influence how these approaches are best...

2010-02-09 15:22:11

M. D. Anderson researchers find better way to predict prognosis in patients treated with aromatase inhibitors; research also suggests a potential means of circumventing drug resistance Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M. D. Anderson Cancer Center report in Clinical Cancer Research. The M. D....